# Viaskin Pertussis Vaccine Trial

> **NCT03035370** · PHASE1 · COMPLETED · sponsor: **DBV Technologies** · enrollment: 102 (actual)

## Conditions studied

- Whooping Cough

## Interventions

- **BIOLOGICAL:** Viaskin PT 25 mcg
- **BIOLOGICAL:** Viaskin PT 50 mcg
- **BIOLOGICAL:** Viaskin PT Placebo
- **BIOLOGICAL:** Boostrix™

## Key facts

- **NCT ID:** NCT03035370
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-05
- **Primary completion:** 2018-04-25
- **Final completion:** 2018-04-25
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2020-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03035370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03035370, "Viaskin Pertussis Vaccine Trial". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03035370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*